Skip to content
ContentLora

    Tip: press / anywhere to search.

    Analysis

    Who can get gene-editing cures? The access and cost debate

    Approved gene-editing therapies are one-time treatments that can cost millions of dollars, and paying for them is reshaping how insurers and governments buy medicines.[1][2] The biggest gap is global: nearly 80% of people with sickle cell disease live in sub-Saharan Africa, while Casgevy's approvals are in North America, Europe and the Middle East.[3][4]

    Editor reviewedStrict sourcingUpdated Gene editing and gene therapyHealth and medicineTech policy
    Show:

    Gene editing has produced a therapy for sickle cell disease that can eliminate severe pain crises for most treated patients in trials.[5] Who actually gets it depends on price, health-system capacity and geography. This page sets out the evidence and the main positions. It is not medical or financial advice.

    The facts

    • CMS states that cell and gene therapies can cost millions of dollars.[1] Vertex set Casgevy’s US list price at $2.2 million per patient in December 2023, and Lyfgenia’s was $3.1 million.[6]
    • The US Cell and Gene Therapy Access Model has CMS negotiate outcomes-based agreements for sickle cell gene therapies from Vertex and Genetix Biotherapeutics. 34 state Medicaid programs, plus Washington DC and Puerto Rico, joined between January 2025 and January 2026.[2]
    • Casgevy treatment requires stem cell collection, editing and myeloablative conditioning (high-dose chemotherapy) before infusion.[7]
    • Casgevy revenue reached $76 million in the second quarter of 2026, up 78% on the prior quarter.[8] It is approved in 39 countries across North America, Europe and the Middle East.[4]
    • Germany agreed reimbursement in May 2026.[9] The FDA extended the US label to children aged 2 and older in July 2026.[10] Vertex estimates this makes about 5,500 more patients eligible.[11]
    • WHO estimates 7.74 million people lived with sickle cell disease in 2021, with 515,000 affected births. Sub-Saharan Africa accounts for nearly 80% of cases.[3]
    • In the US, about 100,000 people have sickle cell disease.[12]

    Interpreting the numbers

    The revenue figures point to steady but gradual uptake, three years after approval.[8][13] Quarterly sales in the tens of millions suggest that a small share of the eligible US and European population has been treated so far, but the companies do not publish exact patient counts in the sources used here. The bottleneck is not only price. Each treatment requires stem cell collection, a manufacturing slot and chemotherapy conditioning at a qualified centre.[7]

    The global gap is starker. Nearly all of Casgevy’s approvals are in high-income regions, while the disease burden is concentrated in sub-Saharan Africa.[4][3]

    What could widen access

    Three developments could change the arithmetic. Vertex and CRISPR Therapeutics had filed in Saudi Arabia and the UK by August 2026 to extend Casgevy to children aged 5 to 11.[14] Vertex says it is doing preclinical work on gentler conditioning regimens, which it says could broaden the eligible population.[15] CRISPR Therapeutics says it is advancing in vivo editing of blood-forming stem cells with lipid nanoparticles, an approach it says could expand who can be treated beyond ex vivo therapy.[16] A competing base-edited therapy, risto-cel, may be filed as early as year-end 2026.[17]

    Each of these addresses a different barrier. Pediatric labels and reimbursement widen who qualifies and who pays. Gentler conditioning and in vivo delivery attack the capacity constraint, because they would reduce the need for stem cell collection, chemotherapy and a qualified transplant centre.[7][16] Competition from a second edited sickle cell therapy could affect price, though neither company has published pricing for the newer products in the sources used here.[17][6] All three remain preclinical, pending or unfiled, so none changes access in 2026.

    Will in vivo editing change the picture?

    In vivo therapies such as lonvo-z are given as a one-time infusion in an outpatient setting, without stem cell collection or conditioning.[18] That could make delivery easier to scale than ex vivo products. But the in vivo programs covered in this course target diseases other than sickle cell, and no price has been announced for lonvo-z in the sources reviewed.[19][20]

    Low-to-moderate confidence: through 2027, access in rich countries will widen gradually through pediatric labels, national reimbursement and outcomes-based contracts.[10][2] Access in sub-Saharan Africa is unlikely to change much on that timescale without new delivery approaches. A base-edited sickle cell therapy filing, planned as early as the end of 2026, would add competition in high-income markets.[17]

    Competing views

    Payment innovation can close the gap

    Outcomes-based deals, national reimbursement and faster approvals are steadily widening who can be treated in rich countries.[2][9][8]

    Access will stay narrow for years

    Cost, specialist centres and chemotherapy conditioning limit uptake, and the countries with most patients have no approval.[1][7][3]

    Simpler in vivo therapies will widen access

    One-time infusions given in outpatient clinics, without stem cell collection or conditioning, could be easier to scale if they are approved.[18][19]

    Questions readers ask

    How much do gene-editing therapies cost?

    CMS says cell and gene therapies can cost millions of dollars. Its Cell and Gene Therapy Access Model negotiates discounts and outcomes-based rebates for sickle cell gene therapies on behalf of state Medicaid programs.[1][2]

    Where is Casgevy available?

    As of August 2026 it was approved in 39 countries across North America, Europe and the Middle East, and Germany agreed reimbursement in May 2026.[4][9]

    Why is Casgevy hard to deliver?

    Each patient's stem cells must be collected and edited, and the patient must undergo myeloablative conditioning with high-dose chemotherapy before the edited cells are infused.[7]

    Where do most people with sickle cell disease live?

    WHO estimates 7.74 million people had sickle cell disease in 2021, and sub-Saharan Africa accounts for nearly 80% of global cases.[3]

    Sources

    Each numbered claim is a statement we checked against the sources listed with it. Status shows how well established it is.

    1. [1]

      CMS notes that cell and gene therapies can cost millions of dollars, and designed its access model to lower prices for states and tie payment to outcomes. confirmedas of 2026-10-10

    2. [2]

      The US Cell and Gene Therapy Access Model is a voluntary CMS program in which CMS negotiates outcomes-based agreements with manufacturers, initially for sickle cell gene therapies from Vertex and Genetix Biotherapeutics; 34 state Medicaid programs plus Washington DC and Puerto Rico joined between January 2025 and January 2026. confirmedas of 2026-10-10

    3. [3]

      WHO estimates that 7.74 million people were living with sickle cell disease in 2021, with 515,000 new births with the disease, and that sub-Saharan Africa accounts for nearly 80% of global cases. confirmedas of 2026-10-10

    4. [4]

      As of August 2026, Casgevy was approved in 39 countries across North America, Europe and the Middle East. confirmedas of 2026-08-03

    5. [5]

      In the data supporting the 2023 FDA approval, 29 of 31 evaluable sickle cell patients (93.5%) were free of severe vaso-occlusive crises for at least 12 consecutive months. confirmedas of 2026-10-10

    6. [6]

      Vertex set Casgevy's US list price at $2.2 million per patient when it was approved in December 2023; Lyfgenia's wholesale acquisition cost was set at $3.1 million. confirmedas of 2026-10-10

    7. [7]

      Treatment with Casgevy involves collecting the patient's own stem cells, editing them, giving myeloablative conditioning (high-dose chemotherapy) to clear the bone marrow, and infusing the edited cells back as a one-time treatment. confirmedas of 2026-10-10

    8. [8]

      Casgevy generated $76 million in revenue in the second quarter of 2026, up 78% from the prior quarter. confirmedas of 2026-10-10

    9. [9]

      In May 2026 Vertex secured reimbursement for Casgevy in Germany for eligible patients aged 12 and older. confirmedas of 2026-10-10

    10. [10]

      On 1 July 2026 the FDA expanded Casgevy's approval to patients aged 2 years and older with sickle cell disease or transfusion-dependent beta-thalassemia, 53 days after filing, under the Commissioner's National Priority Voucher pilot program. confirmedas of 2026-10-10

    11. [11]

      Vertex estimates that about 5,500 more patients with sickle cell disease or beta-thalassemia became eligible for Casgevy with the 2026 pediatric approval. confirmedas of 2026-10-10

    12. [12]

      Sickle cell disease affects approximately 100,000 people in the United States. confirmedas of 2026-10-10

    13. [13]

      On 8 December 2023 the FDA approved Casgevy, the first FDA-approved therapy using CRISPR/Cas9, for people aged 12 and older with sickle cell disease and recurrent vaso-occlusive crises. confirmedas of 2026-10-10

    14. [14]

      As of August 2026 Vertex and CRISPR Therapeutics had completed regulatory submissions in Saudi Arabia and the United Kingdom to extend Casgevy to children aged 5 to 11. confirmedas of 2026-08-03

    15. [15]

      Vertex says it is advancing preclinical work on gentler conditioning regimens for Casgevy, which it says could broaden the eligible patient population. confirmedas of 2026-08-03

    16. [16]

      CRISPR Therapeutics says it is advancing in vivo editing of blood-forming stem cells using lipid nanoparticle delivery, an approach it says could expand the treatable population for sickle cell disease and beta-thalassemia beyond ex vivo therapy. confirmedas of 2026-08-03

    17. [17]

      Beam plans to submit a Biologics License Application for risto-cel (formerly BEAM-101), a base-edited cell therapy for sickle cell disease, as early as year-end 2026. reportedas of 2026-08-04· forecast

    18. [18]

      Lonvo-z (lonvoguran ziclumeran) is Intellia's one-time, in vivo CRISPR/Cas9 treatment for hereditary angioedema, designed to permanently lower kallikrein by inactivating the KLKB1 gene, and given in an outpatient setting. confirmedas of 2026-10-10

    19. [19]

      Early CRISPR therapies edited cells outside the body (ex vivo); newer approaches deliver the editor into the patient (in vivo), which a 2025 review notes faces lower delivery efficiency, off-target effects and instability. confirmedas of 2026-10-10

    20. [20]

      On 8 September 2026 Intellia said the FDA had accepted its lonvo-z application with Priority Review and a target action date of 10 March 2027; the company says lonvo-z would be the world's first in vivo CRISPR-based therapy if approved. confirmedas of 2026-10-10

    Revision history (2)
    1. Page created.
    2. Added list prices and a section on developments that could widen access (pediatric filings, gentler conditioning, in vivo stem-cell editing, competition).

    Created Oct 10, 2026. Last reviewed by an editor on Oct 10, 2026. Next scheduled review: Jan 10, 2027.

    Cite this page

    "Who can get gene-editing cures? The access and cost debate." ContentLora, updated Oct 10, 2026. https://contentlora.com/analysis/gene-therapy-access-debate

    Spotted an error? Suggest a correction or emailcorrections@contentlora.com.

    Keep exploring

    ☰ Contents